Scriba, TJ, Fiore-Gartland, A, Penn-Nicholson, A, Mulenga, H, Kimbung Mbandi, S, Borate, B, Mendelsohn, SC, Hadley, K, Hikuam, C, Kaskar, M, Musvosvi, M, Bilek, N, Self, S, Sumner, T, White, RG, Erasmus, M, Jaxa, L, Raphela, R, Innes, C, Brumskine, W, Hiemstra, A, Malherbe, ST, Hassan-Moosa, R, Tameris, M, Walzl, G, Naidoo, K, Churchyard, G and Hatherill, M. 2021. RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial. [Online]. University of Cape Town. Available from: https://doi.org/10.25375/uct.13573337.v1
Scriba, TJ, Fiore-Gartland, A, Penn-Nicholson, A, Mulenga, H, Kimbung Mbandi, S, Borate, B, Mendelsohn, SC, Hadley, K, Hikuam, C, Kaskar, M, Musvosvi, M, Bilek, N, Self, S, Sumner, T, White, RG, Erasmus, M, Jaxa, L, Raphela, R, Innes, C, Brumskine, W, Hiemstra, A, Malherbe, ST, Hassan-Moosa, R, Tameris, M, Walzl, G, Naidoo, K, Churchyard, G and Hatherill, M. RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial [Internet]. University of Cape Town; 2021. Available from: https://doi.org/10.25375/uct.13573337.v1
Scriba, TJ, Fiore-Gartland, A, Penn-Nicholson, A, Mulenga, H, Kimbung Mbandi, S, Borate, B, Mendelsohn, SC, Hadley, K, Hikuam, C, Kaskar, M, Musvosvi, M, Bilek, N, Self, S, Sumner, T, White, RG, Erasmus, M, Jaxa, L, Raphela, R, Innes, C, Brumskine, W, Hiemstra, A, Malherbe, ST, Hassan-Moosa, R, Tameris, M, Walzl, G, Naidoo, K, Churchyard, G and Hatherill, M (2021). RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial. [Data Collection]. University of Cape Town. https://doi.org/10.25375/uct.13573337.v1
Description
RISK11 transcriptomic signature scores for 20,207 volunteers who were screened at five geographically diverse sites across South Africa. Signature scores were computed from QC'ed gene expression measurements performed by microfluidic RT-qPCR on mRNA derived from whole blood collected in PAXgene tubes. Participants were randomised into three groups and followed-up for 15 months to evaluate diagnostic and prognostic performance of RISK11 and to evaluate efficacy of high-dose isoniazid and rifapentine for prevention of incident TB.
Keywords
| Data capture method | Experiment: Laboratory |
|---|---|
| Date (Date published in a 3rd party system) | 15 January 2021 |
| Language(s) of written materials | English |
| Data Creators | Scriba, TJ, Fiore-Gartland, A, Penn-Nicholson, A, Mulenga, H, Kimbung Mbandi, S, Borate, B, Mendelsohn, SC, Hadley, K, Hikuam, C, Kaskar, M, Musvosvi, M, Bilek, N, Self, S, Sumner, T, White, RG, Erasmus, M, Jaxa, L, Raphela, R, Innes, C, Brumskine, W, Hiemstra, A, Malherbe, ST, Hassan-Moosa, R, Tameris, M, Walzl, G, Naidoo, K, Churchyard, G and Hatherill, M |
|---|---|
| LSHTM Faculty/Department | Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology (-2023) |
| Participating Institutions | London School of Hygiene & Tropical Medicine, London, United Kingdom |
| Date Deposited | 15 Feb 2021 09:52 |
|---|---|
| Last Modified | 08 Jul 2021 12:49 |
| Publisher | University of Cape Town |
